CDA | Evidence Driven
CDA | Evidence Driven

Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Export to CSV
Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Treanda Bendamustine hydrochloride Chronic Lymphocytic Leukemia (first-line) Reimburse with clinical criteria and/or conditions Complete
Treanda Bendamustine hydrochloride Non-Hodgkin Lymphoma and Mantle Cell Lymphoma Reimburse Complete
Treanda (in combination with rituximab) Bendamustine hydrochloride Chronic Lymphocytic Leukemia Withdrawn
Trecondyv treosulfan Conditioning treatment prior to stem cell transplantation for acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) (pediatric) CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Trecondyv treosulfan Conditioning treatment prior to stem cell transplantation for acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) Reimburse with clinical criteria and/or conditions Complete
Trelegy Ellipta fluticasone furoate/umeclidinium bromide/vilanterol trifenatate Asthma, maintenance CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Trelegy Ellipta fluticasone furoate umeclidinium vilanterol Chronic obstructive pulmonary disease (COPD) Reimburse with clinical criteria and/or conditions Complete
Trelstar Triptorelin pamoate Cancer, prostate List in a similar manner to other drugs in class Complete
Tremfya guselkumab Psoriatic arthritis Reimburse with clinical criteria and/or conditions Complete
Tremfya guselkumab Psoriasis, moderate to severe plaque Reimburse with clinical criteria and/or conditions Complete
Tresiba insulin degludec Diabetes mellitus, Type 1 & 2 Reimburse with clinical criteria and/or conditions Complete
Tridural Tramadol hydrochloride Pain Do not list Complete
Trikafta elexacaftor / tezacaftor / ivacaftor and ivacaftor Cystic fibrosis, F508del CFTR mutation Reimburse with clinical criteria and/or conditions Complete
Trikafta elexacaftor/tezacaftor/ivacaftor and ivacaftor Cystic fibrosis, F508del CFTR mutation, 2 years and older Reimburse with clinical criteria and/or conditions Complete
Trikafta elexacaftor/tezacaftor/ivacaftor and ivacaftor Cystic fibrosis, F508del CFTR mutation, 6 years and older Reimburse with clinical criteria and/or conditions Complete
Trikafta elexacaftor/tezacaftor/ivacaftor and ivacaftor Cystic fibrosis, F508del or responsive CFTR mutation, 2 years and older Active
Trintellix Vortioxetine Depression, major depressive disorder Withdrawn
Trintellix vortioxetine hydrobromide Major depressive disorder (MDD), adults. Reimburse with clinical criteria and/or conditions Complete
Trisenox Arsenic Trioxide Acute Promyelocytic Leukemia Reimburse Complete
Triumeq Dolutegravir / abacavir / lamivudine HIV Infection List with criteria/condition Complete
Trodelvy sacituzumab govitecan HR+, HER2− advanced or metastatic breast cancer Reimburse with clinical criteria and/or conditions Complete
Trodelvy sacituzumab govitecan Locally advanced or metastatic triple-negative breast cancer Reimburse with clinical criteria and/or conditions Complete
Trosec Trospium chloride Bladder, overactive List with clinical criteria and/or conditions Complete
Trulicity dulaglutide Diabetes mellitus, Type 2 Reimburse with clinical criteria and/or conditions Complete
Truqap capivasertib HR-positive, HER2-negative locally advanced or metastatic breast cancer Active
Last Updated : June 30, 2024